Alternative testing strategies for medical diagnostics
NanoTEST was a four-year FP7 project which took place between 2008-2012, co-ordinated by Dr Maria Dusinska of NILU, Norway.
The project aimed to develop methodology alternative testing strategies and high-throughput toxicity testing protocols using in vitro and in silico methods for the risk assessment of nanoparticles used in medical diagnostics.
The specific aims of NanoTEST were to:
- Define parameters describing properties of NP, and to carry out particle charactersation;
- Study specific and nonspecific interactions of NP with molecules, cells and organs and to develop in vitro methods which can identify the toxicological potential of NP;
- Validate in vitro findings in short-term in vivo models, to study manifestation of particle effects in animals and humans, and to assess individual susceptibility in the response to NPs;
- Perform Structure-Activity modelling and physiologically-based pharmacokinetic (PBPK) modelling of NP;
- Adapt the most advanced and promising assays for high-throughput automated systems and to prepare for validation by ECVAM.
NanoTEST defined reference biological markers, using relevant in vitro models of toxicology which can be used by other researchers and technologists to test the possible toxicity of medical (or other) NP, in order to reduce animal experiments as much as possible.
IOM was primarily involved in QSAR & PBPK modelling activities and led the dissemination of the project findings.
The final summary report of the NanoTEST project is available to download here.
In addition, the results of the NanoTEST project were published as a series of articles in a Supplement to Volume 9 of the Nanotoxicology journal.
For further information, please visit the Cordis webpage or contact us.